Triptorelin GnRHExplore study findings
What longer follow-up adds to triptorelin research in early puberty
2 numbered sourcesSource years 2025, 2026
Peptides are short amino-acid chains built with peptide bonds. When one activates a hormone receptor, its effect can change as the receptor adapts to prolonged stimulation. Triptorelin is a synthetic ten-amino-acid agonist of the receptor for gonadotropin-releasing hormone, or GnRH. An extended-release U.S. product, Triptodur, is approved for central precocious puberty in children age two and older. A 2026 report followed girls who received a long-acting triptorelin formulation to see how hormone measurements and physical development changed beyond the first year. [1, 2]
The researchers analyzed clinical records from 37 girls. Most measured luteinizing hormone results met the study's suppression criterion. Two girls had values above that criterion at one earlier assessment and fell below it on subsequent measurements. Estradiol was generally suppressed in the samples that were taken. Breast development stabilized or regressed for most girls, while a smaller group showed further development. Each of those findings describes a particular measure. The sample included girls with different lengths of follow-up and some missing measurements at individual time points. [1]
The researchers also compared bone age with chronological age. They found the average gap narrowed over time by that measure, and predicted adult height rose by an average of roughly five centimeters. A height prediction is based on the growth and bone-age measurements available during childhood. It can change as a child's growth pattern changes, and the estimate in this study cannot be read as a measured difference in adult height. [1]
Following children for longer gives researchers a way to see whether early hormone changes persist and whether physical findings move in the same direction. Because this cohort had no comparison group, it cannot quantify a difference relative to another formulation or the course that would have occurred without treatment. Its direct contribution is the pattern observed over time in girls receiving the studied formulation. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Foreman A, Klein KO, Vargas Trujillo M. Efficacy and outcomes of 6-month triptorelin formulation in girls treated for central precocious puberty for 24 months and beyond. Journal of Pediatric Endocrinology and Metabolism (publication 2026-01-26). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
